Roivant Sciences Ltd.
brepocitinib
lichen planopilaris
Resolved
151days ago
Phase 2 readout · Feb 6, 2026
What's at stake
Phase 2 trial results for brepocitinib in lichen planopilaris are due Feb 6, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Roivant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS).”